Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Aclaris Therapeutics Inc (NASDAQ: ACRS) closed at $1.79 in the last session, down -3.24% from day before closing price of $1.85. In other words, the price has decreased by -$3.24 from its previous closing price. On the day, 1.0 million shares were traded. ACRS stock price reached its highest trading level at $1.85 during the session, while it also had its lowest trading level at $1.745.
Ratios:
We take a closer look at ACRS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.88 and its Current Ratio is at 3.88. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 28, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $8.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 19 ’24 when Mehra Anand bought 666,666 shares for $2.25 per share. The transaction valued at 1,499,998 led to the insider holds 710,030 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 193914272 and an Enterprise Value of 102974600. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.55 while its Price-to-Book (P/B) ratio in mrq is 1.47. Its current Enterprise Value per Revenue stands at 6.133 whereas that against EBITDA is -1.768.
Stock Price History:
The Beta on a monthly basis for ACRS is 0.28, which has changed by 0.40944886 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, ACRS has reached a high of $5.17, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 14.39%, while the 200-Day Moving Average is calculated to be -10.63%.
Shares Statistics:
According to the various share statistics, ACRS traded on average about 1.16M shares per day over the past 3-months and 956240 shares per day over the past 10 days. A total of 108.33M shares are outstanding, with a floating share count of 92.29M. Insiders hold about 14.81% of the company’s shares, while institutions hold 72.92% stake in the company. Shares short for ACRS as of 1753920000 were 6551165 with a Short Ratio of 5.65, compared to 1751241600 on 7485345. Therefore, it implies a Short% of Shares Outstanding of 6551165 and a Short% of Float of 7.21.
Earnings Estimates
As of right now, 4.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.12 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.51 and -$0.55 for the fiscal current year, implying an average EPS of -$0.53. EPS for the following year is -$0.63, with 5.0 analysts recommending between -$0.41 and -$0.87.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $1.59M. It ranges from a high estimate of $2.1M to a low estimate of $1M. As of the current estimate, Aclaris Therapeutics Inc’s year-ago sales were $4.35MFor the next quarter, 6 analysts are estimating revenue of $1.58M. There is a high estimate of $1.98M for the next quarter, whereas the lowest estimate is $1M.
A total of 6 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $7.2M, while the lowest revenue estimate was $5.2M, resulting in an average revenue estimate of $6.34M. In the same quarter a year ago, actual revenue was $18.72MBased on 8 analysts’ estimates, the company’s revenue will be $5.05M in the next fiscal year. The high estimate is $10M and the low estimate is $900k.
